Gyroscope Therapeutics

London Exchange

Novartis to buy Syncona’s Gyroscope Therapeutics for $1.5bn
ByBernice Miles December 22, 2021October 24, 2023

LONDON, UK: Syncona Ltd has been reached to sell its portfolio company Gyroscope Therapeutics Holdings to Novartis for up to $1.5 billion on a cash and debt free basis. Novartis will make with an upfront payment of $800 million and up to $700 million potentially due upon the achievement of certain customary milestones related to…

Read More Novartis to buy Syncona’s Gyroscope Therapeutics for $1.5bn
London Exchange

Sanofi to invest up to $60 million in Gyroscope Therapeutics
ByNNR November 8, 2021October 24, 2023

LONDON, UK: Sanofi, a global biopharmaceutical company, has committed to invest up to $60 million in equity of Gyroscope Therapeutics Holdings. Gyroscope plans to use proceeds from this investment to support funding of ongoing clinical trials of GT005 in GA. GT005 has been granted Fast Track designation by the U.S. Food and Drug Administration and…

Read More Sanofi to invest up to $60 million in Gyroscope Therapeutics